Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 84 of 95, showing 5 Applications out of 471 total, starting on record 416, ending on 420

# Protocol No Study Title Investigator(s) & Site(s)

416.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

417.

ECCT/18/01/01   Mal 094
    Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age.   
Principal Investigator(s)
1. Aaron Samuels
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral hospital (Siaya county)
2. Ngiya Health Center (Siaya county)
3. Kogelo Health Center (Siaya county)
4. Tingwangi (Siaya county)
5. Mulaha (Siaya county)
6. Nyathengo (Siaya county)
7. Bal Olengo (Siaya county)
 
View

418.

ECCT/21/04/01   FujiLAM Study
    Diagnostic performance of a novel lipoarabinomannan test (FujiLAM) to detect tuberculosis in HIV-positive patients in Kenya   
Principal Investigator(s)
1. Helena Huerga
Site(s) in Kenya
Homabay County Teaching and Referral Hospital
 
View

419.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
View

420.

ECCT/21/03/07   CHIMES
    AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View